543 related articles for article (PubMed ID: 31661003)
1. Recent advances in nanotheranostics for triple negative breast cancer treatment.
Thakur V; Kutty RV
J Exp Clin Cancer Res; 2019 Oct; 38(1):430. PubMed ID: 31661003
[TBL] [Abstract][Full Text] [Related]
2. Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances.
Miller-Kleinhenz JM; Bozeman EN; Yang L
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2015; 7(6):797-816. PubMed ID: 25966677
[TBL] [Abstract][Full Text] [Related]
3. Nanotheranostics for Diagnosis and Treatment of Breast Cancer.
Patel P; Kumar K; Jain VK; Popli H; Yadav AK; Jain K
Curr Pharm Des; 2023; 29(10):732-747. PubMed ID: 36999427
[TBL] [Abstract][Full Text] [Related]
4. Targeted treatment of triple-negative-breast cancer through pH-triggered tumour associated macrophages using smart theranostic nanoformulations.
Scialla S; Hanafy MS; Wang JL; Genicio N; Costa Da Silva M; Costa M; Oliveira-Pinto S; Baltazar F; Gallo J; Cui Z; Bañobre-López M
Int J Pharm; 2023 Feb; 632():122575. PubMed ID: 36603672
[TBL] [Abstract][Full Text] [Related]
5. Theranostics for Triple-Negative Breast Cancer.
Choi H; Kim K
Diagnostics (Basel); 2023 Jan; 13(2):. PubMed ID: 36673082
[TBL] [Abstract][Full Text] [Related]
6. Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue.
Gote V; Nookala AR; Bolla PK; Pal D
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925129
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticle drug delivery systems responsive to tumor microenvironment: Promising alternatives in the treatment of triple-negative breast cancer.
Cao Y; Meng F; Cai T; Gao L; Lee J; Solomevich SO; Aharodnikau UE; Guo T; Lan M; Liu F; Li Q; Viktor T; Li D; Cai Y
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(2):e1950. PubMed ID: 38528388
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
9. RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC.
Kim SJ; Ju JS; Kang MH; Eun JW; Kim YH; Raninga PV; Khanna KK; Győrffy B; Pack CG; Han HD; Lee HJ; Gong G; Shin Y; Mills GB; Eyun SI; Park YY
Theranostics; 2020; 10(18):7974-7992. PubMed ID: 32724453
[TBL] [Abstract][Full Text] [Related]
10. Voyage of theranostic liposomes for imaging and therapy.
Sachin M; Sachin D; Dinesh S
J Cosmet Laser Ther; 2017 Aug; 19(4):245-249. PubMed ID: 28135901
[TBL] [Abstract][Full Text] [Related]
11. ZD2-Engineered Gold Nanostar@Metal-Organic Framework Nanoprobes for T
Zhang L; Liu C; Gao Y; Li Z; Xing J; Ren W; Zhang L; Li A; Lu G; Wu A; Zeng L
Adv Healthc Mater; 2018 Dec; 7(24):e1801144. PubMed ID: 30370656
[TBL] [Abstract][Full Text] [Related]
12. Receptor-Targeted Surface-Engineered Nanomaterials for Breast Cancer Imaging and Theranostic Applications.
Ahmad J; Rizwanullah M; Suthar T; Albarqi HA; Ahmad MZ; Vuddanda PR; Khan MA; Jain K
Crit Rev Ther Drug Carrier Syst; 2022; 39(6):1-44. PubMed ID: 35997100
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticle-Mediated Immunotherapy in Triple-Negative Breast Cancer.
Wang R; Huang X; Chen X; Zhang Y
ACS Biomater Sci Eng; 2024 Jun; 10(6):3568-3598. PubMed ID: 38815129
[TBL] [Abstract][Full Text] [Related]
14. Fibronectin-Targeting and Cathepsin B-Activatable Theranostic Nanoprobe for MR/Fluorescence Imaging and Enhanced Photodynamic Therapy for Triple Negative Breast Cancer.
Wang Y; Jiang L; Zhang Y; Lu Y; Li J; Wang H; Yao D; Wang D
ACS Appl Mater Interfaces; 2020 Jul; 12(30):33564-33574. PubMed ID: 32633941
[TBL] [Abstract][Full Text] [Related]
15. Global trends in nanomedicine research on triple negative breast cancer: a bibliometric analysis.
Teles RHG; Moralles HF; Cominetti MR
Int J Nanomedicine; 2018; 13():2321-2336. PubMed ID: 29713164
[TBL] [Abstract][Full Text] [Related]
16. Silencing of Pyruvate Kinase M2
Huang S; Zhu W; Zhang F; Chen G; Kou X; Yang X; Ouyang G; Shen J
ACS Appl Mater Interfaces; 2021 Dec; 13(48):56972-56987. PubMed ID: 34797638
[TBL] [Abstract][Full Text] [Related]
17. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer.
Ye F; Dewanjee S; Li Y; Jha NK; Chen ZS; Kumar A; Vishakha ; Behl T; Jha SK; Tang H
Mol Cancer; 2023 Jul; 22(1):105. PubMed ID: 37415164
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in triple-negative breast cancer.
Katz H; Alsharedi M
Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
[TBL] [Abstract][Full Text] [Related]
19. Nanotechnology-mediated delivery of resveratrol as promising strategy to improve therapeutic efficacy in triple negative breast cancer (TNBC): progress and promises.
Ahmad J; Ahamad J; Algahtani MS; Garg A; Shahzad N; Ahmad MZ; Imam SS
Expert Opin Drug Deliv; 2024 Feb; 21(2):229-244. PubMed ID: 38344809
[TBL] [Abstract][Full Text] [Related]
20. Theranostics of Triple-Negative Breast Cancer Based on Conjugated Polymer Nanoparticles.
Jin G; He R; Liu Q; Dong Y; Lin M; Li W; Xu F
ACS Appl Mater Interfaces; 2018 Apr; 10(13):10634-10646. PubMed ID: 29323875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
